Comprehensive molecular and immunohistochemical analysis of advanced renal cell carcinoma patients treated with mTOR inhibitors.

被引：1
|
作者：
Garcaa-Donas, Jesas
Roldan, Jose Maria
Lainez, Nuria
Castellano, Daniel E.
Gonzalez, Emilio Esteban
Climent, Miguel A.
Puente, Javier
Francisco Rodriguez-Moreno, Juan
Alonso Gordoa, Teresa
Gonzalez del Alba, Aranzazu
Angel Arranz, Jose
Santos, Maria
Hernando Polo, Susana
Domenech, Montserrat
Rodriguez, Laura
Herrador, Alejandro
Isabel Saez, M.
Gallardo Diaz, Enrique
Maria Gutierrez, Ana
Rodriguez-Antona, Cristina
机构：
[1] Fdn Hosp Madrid, Madrid, Spain
[2] Spanish Camcer Res Ctr, Madrid, Spain
[3] Complejo Hosp Navarra, Pamplona, Spain
[4] Hosp 12 Octubre, Madrid, Spain
[5] Hosp Univ Cent Asturias, Oviedo, Spain
[6] Fdn Inst Valenciano Oncol, Valencia, Spain
[7] Hosp Univ Clin San Carlos, Madrid, Spain
[8] Hosp Univ HM Sanchinarro, Madrid, Spain
[9] Hosp Univ Ramon y Cajal, Madrid, Spain
[10] Son Espases Univ Hosp, Palma De Mallorca, Spain
[11] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[12] Spanish Natl Canc Res Ctr, Madrid, Spain
[13] Hosp Univ Fdn Alcorcon, Alcorcon, Spain
[14] Hosp Althaia, Manresa, Spain
[15] Hosp Univ Fuenlabrada, Fuenlabrada, Spain
[16] Clara Campal Comprehens Canc Ctr CIOCC, Madrid, Spain
[17] Hosp Univ Virgen de la Victoria & Reg Malaga, CNIO IBIMA Genitourinary Canc Res Unit, CRIS Canc Fdn Prostate Canc Res Grp, Inst Biomed Res Malaga, Malaga, Spain
[18] Univ Autonoma Barcelona, Parc Tauli Sabadell Hosp Univ, Inst Invest Innovacio Parc Tauli, Dept Oncol, Sabadell, Spain
[19] Hosp Puerta Sur, Mostoles, Spain
[20] Spanish Natl Canc Res Ctr CNIO, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4559
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4559
引用
收藏
页数：1
相关论文
共 50 条
  • [1] mTOR Inhibitors in Advanced Renal Cell Carcinoma
    Voss, Martin H.
    Molina, Ana M.
    Motzer, Robert J.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (04) : 835 - +
  • [2] Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
    Derosa, Lisa
    Routy, Bertrand
    Enot, David
    Baciarello, Giulia
    Massard, Christophe
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [3] Potential role of hypovitaminosis D in renal cell carcinoma patients treated with immune-checkpoint inhibitors.
    Bersanelli, Melissa
    Vaglio, Augusto
    Sverzellati, Nicola
    Galetti, Maricla
    Incerti, Monia
    Parziale, Raffaele
    Corrado, Michele
    Cosenza, Agnese
    Ferri, Leonarda
    Leonardi, Francesco
    Buti, Sebastiano
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [4] mTOR Pathway Activation Characterizes a Subset of Unclassified Renal Cell Carcinoma: Immunohistochemical, Molecular and Histologic Analysis
    Kong, M. X.
    Brannon, A. R. R.
    Won, H.
    Gandhi, A.
    Al-Ahmadie, H. A.
    Fine, S. W.
    Gopalan, A.
    Russo, P.
    Berger, M. F.
    Tickoo, S. K.
    Reuter, V. E.
    Chen, Y-B
    MODERN PATHOLOGY, 2014, 27 : 241A - 241A
  • [5] mTOR Pathway Activation Characterizes a Subset of Unclassified Renal Cell Carcinoma: Immunohistochemical, Molecular and Histologic Analysis
    Kong, M. X.
    Brannon, A. R. R.
    Won, H.
    Gandhi, A.
    Al-Ahmadie, H. A.
    Fine, S. W.
    Gopalan, A.
    Russo, P.
    Berger, M. F.
    Tickoo, S. K.
    Reuter, V. E.
    Chen, Y-B
    LABORATORY INVESTIGATION, 2014, 94 : 241A - 241A
  • [6] Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma
    M. Jebali
    R. Elaidi
    M. Brizard
    J. Fouque
    C. Takouchop
    B. Sabatier
    S. Oudard
    J. Medioni
    BMC Cancer, 17
  • [7] Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma
    Jebali, M.
    Elaidi, R.
    Brizard, M.
    Fouque, J.
    Takouchop, C.
    Sabatier, B.
    Oudard, S.
    Medioni, J.
    BMC CANCER, 2017, 17
  • [8] Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma
    Rodriguez-Pascual, Jesus
    Cheng, Elaine
    Maroto, Pablo
    Duran, Ignacio
    ANTI-CANCER DRUGS, 2010, 21 (05) : 478 - 486
  • [9] Differentiating mTOR inhibitors in renal cell carcinoma
    Pal, Sumanta K.
    Quinn, David I.
    CANCER TREATMENT REVIEWS, 2013, 39 (07) : 709 - 719
  • [10] TREATMENT OF HEMODIALYZED PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WITH MTOR INHIBITORS
    Masini, Cristina
    Felici, Alessandra
    Di Lorenzo, Giuseppe
    Onofri, Azzurra
    Prati, Veronica
    Mighali, Pasquale
    Conte, Pier Franco
    Sabbatini, Roberto
    ANTICANCER RESEARCH, 2012, 32 (05) : 1873 - 1874
12345